JP2022553702A5 - - Google Patents
Info
- Publication number
- JP2022553702A5 JP2022553702A5 JP2022523574A JP2022523574A JP2022553702A5 JP 2022553702 A5 JP2022553702 A5 JP 2022553702A5 JP 2022523574 A JP2022523574 A JP 2022523574A JP 2022523574 A JP2022523574 A JP 2022523574A JP 2022553702 A5 JP2022553702 A5 JP 2022553702A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyldiyl
- peg
- amino
- pep
- thienoazepine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962926333P | 2019-10-25 | 2019-10-25 | |
| US62/926,333 | 2019-10-25 | ||
| US202062984184P | 2020-03-02 | 2020-03-02 | |
| US62/984,184 | 2020-03-02 | ||
| PCT/US2020/057167 WO2021081407A1 (en) | 2019-10-25 | 2020-10-23 | Thienoazepine immunoconjugates, and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022553702A JP2022553702A (ja) | 2022-12-26 |
| JP2022553702A5 true JP2022553702A5 (enExample) | 2023-10-20 |
| JP7709431B2 JP7709431B2 (ja) | 2025-07-16 |
Family
ID=73544268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022523574A Active JP7709431B2 (ja) | 2019-10-25 | 2020-10-23 | チエノアゼピン、イムノコンジュゲート、及びそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11654199B2 (enExample) |
| EP (1) | EP4048315B1 (enExample) |
| JP (1) | JP7709431B2 (enExample) |
| KR (1) | KR20220088901A (enExample) |
| AU (1) | AU2020369652A1 (enExample) |
| BR (1) | BR112022007719A2 (enExample) |
| CA (1) | CA3155077A1 (enExample) |
| IL (1) | IL292396A (enExample) |
| MX (1) | MX2022004875A (enExample) |
| TW (1) | TWI857167B (enExample) |
| WO (1) | WO2021081407A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109843327B (zh) | 2016-07-07 | 2022-05-13 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
| WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| TWI857167B (zh) | 2019-10-25 | 2024-10-01 | 美商博特生物治療公司 | 噻吩并氮呯免疫結合物及其用途 |
| EP4048314A1 (en) * | 2019-10-25 | 2022-08-31 | Bolt Biotherapeutics, Inc. | Macromolecule-supported thienoazepine compounds, and uses thereof |
| US20230293716A1 (en) * | 2020-05-08 | 2023-09-21 | Bolt Biotherapeutics, Inc. | Elastase-substrate, peptide linker immunoconjugates, and uses thereof |
| IL300316A (en) * | 2020-08-13 | 2023-04-01 | Bolt Biotherapeutics Inc | Immune conjugates of pyrazolozapines and their uses |
| JP2024539993A (ja) * | 2021-10-29 | 2024-10-31 | ボルト バイオセラピューティクス、インコーポレーテッド | システイン変異抗体を含むｔｌｒアゴニスト免疫複合体、及びその使用 |
| EP4450496A4 (en) * | 2021-12-16 | 2025-12-24 | Duality Biologics Suzhou Co Ltd | TLR MODULATOR AND ITS USAGE |
| KR20230134769A (ko) * | 2022-03-15 | 2023-09-22 | 에이치엘만도 주식회사 | 유압 밸브 블록 및 이를 포함하는 브레이크의 구동장치 |
| WO2024129956A1 (en) * | 2022-12-15 | 2024-06-20 | Bolt Biotherapeutics, Inc. | Thienoazepine immunoconjugates, and uses thereof |
| WO2026050214A1 (en) * | 2024-08-27 | 2026-03-05 | Bolt Biotherapeutics, Inc. | Anti-claudin, tlr agonist immunoconjugates and uses thereof |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US723288A (en) | 1901-10-26 | 1903-03-24 | Harry South Lewis | Cipher-key for cryptographic codes. |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5874540A (en) | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| NZ507557A (en) | 1998-05-06 | 2003-10-31 | Genentech Inc | Protein purification by ion exchange chromatography |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| JP2003531149A (ja) | 2000-04-13 | 2003-10-21 | ザ・ロツクフエラー・ユニバーシテイ | 抗体由来の免疫応答の増強 |
| US7273608B2 (en) | 2004-03-11 | 2007-09-25 | City Of Hope | Humanized anti-CEA T84.66 antibody and uses thereof |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| WO2006073921A2 (en) | 2004-12-30 | 2006-07-13 | The Rockefeller University | Compositions and methods for enhanced dendritic cell maturation and function |
| US20080286819A1 (en) | 2005-11-07 | 2008-11-20 | Ravetch Jeffrey V | Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof |
| JP5399712B2 (ja) | 2005-12-21 | 2014-01-29 | アムゲン リサーチ （ミュンヘン） ゲーエムベーハー | 可溶性ｃｅａに対する抵抗性を有する医薬組成物 |
| CL2008001334A1 (es) | 2007-05-08 | 2008-09-22 | Genentech Inc | Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer. |
| NZ584514A (en) | 2007-10-19 | 2012-07-27 | Genentech Inc | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates |
| CN105669553A (zh) | 2009-08-18 | 2016-06-15 | 文蒂雷克斯药品公司 | 作为toll样受体调节剂的取代的苯并氮杂* |
| DK2532680T3 (da) | 2010-02-04 | 2015-07-20 | Toray Industries | Medicinsk sammensætning til behandling og/eller forebyggelse af cancer |
| US20120121615A1 (en) | 2010-11-17 | 2012-05-17 | Flygare John A | Alaninyl maytansinol antibody conjugates |
| PE20141017A1 (es) | 2011-03-02 | 2014-08-25 | Roche Glycart Ag | Anticuerpos del cea |
| RU2595400C2 (ru) | 2011-08-04 | 2016-08-27 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли |
| US9181348B2 (en) | 2011-08-04 | 2015-11-10 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| EP2740794B1 (en) | 2011-08-04 | 2018-04-04 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| PL2740793T3 (pl) | 2011-08-04 | 2018-04-30 | Toray Industries, Inc. | Kompozycja leku do leczenia i/lub zapobiegania nowotworowi |
| US9260513B2 (en) | 2012-02-21 | 2016-02-16 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| ES2739612T3 (es) | 2012-02-21 | 2020-02-03 | Toray Industries | Composición farmacéutica para el tratamiento de cáncer |
| WO2013125654A1 (ja) | 2012-02-21 | 2013-08-29 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| BR112014021103A2 (pt) | 2012-02-21 | 2019-10-15 | Toray Industries, Inc | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo |
| PL2876447T3 (pl) | 2012-07-19 | 2020-05-18 | Toray Industries, Inc. | Sposób wykrywania nowotworu |
| MX357292B (es) | 2012-07-19 | 2018-07-04 | Toray Industries | Método para detectar cáncer. |
| DK3199552T3 (da) | 2012-11-20 | 2020-03-30 | Sanofi Sa | Anti-ceacam5-antistoffer og anvendelser heraf |
| AU2014303375B2 (en) | 2013-08-09 | 2019-07-04 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| BR112016014952A2 (pt) | 2014-02-10 | 2017-09-19 | Merck Patent Gmbh | Inibição direcionada de tgfbeta |
| AU2015349878A1 (en) | 2014-11-21 | 2017-05-25 | Bristol-Myers Squibb Company | Antibodies against CD73 and uses thereof |
| CN109890417A (zh) | 2016-10-28 | 2019-06-14 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| US20190336615A1 (en) | 2017-01-27 | 2019-11-07 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| CA3100544A1 (en) * | 2018-05-17 | 2019-11-21 | Bolt Biotherapeutics, Inc. | Immunoconjugates |
| JP7558205B2 (ja) | 2019-06-13 | 2024-09-30 | ボルト バイオセラピューティクス、インコーポレーテッド | 高分子支持アミノベンズアピン化合物 |
| US20200390899A1 (en) | 2019-06-13 | 2020-12-17 | Bolt Biotherapeutics, Inc. | Aminobenzazepine compounds, immunoconjugates, and uses thereof |
| EP4048314A1 (en) | 2019-10-25 | 2022-08-31 | Bolt Biotherapeutics, Inc. | Macromolecule-supported thienoazepine compounds, and uses thereof |
| TWI857167B (zh) | 2019-10-25 | 2024-10-01 | 美商博特生物治療公司 | 噻吩并氮呯免疫結合物及其用途 |
-
2020
- 2020-10-23 TW TW109136997A patent/TWI857167B/zh active
- 2020-10-23 KR KR1020227017386A patent/KR20220088901A/ko not_active Withdrawn
- 2020-10-23 MX MX2022004875A patent/MX2022004875A/es unknown
- 2020-10-23 US US17/078,467 patent/US11654199B2/en active Active
- 2020-10-23 JP JP2022523574A patent/JP7709431B2/ja active Active
- 2020-10-23 BR BR112022007719A patent/BR112022007719A2/pt unknown
- 2020-10-23 AU AU2020369652A patent/AU2020369652A1/en not_active Abandoned
- 2020-10-23 CA CA3155077A patent/CA3155077A1/en active Pending
- 2020-10-23 WO PCT/US2020/057167 patent/WO2021081407A1/en not_active Ceased
- 2020-10-23 EP EP20811787.9A patent/EP4048315B1/en active Active
- 2020-10-23 IL IL292396A patent/IL292396A/en unknown
-
2023
- 2023-03-06 US US18/118,105 patent/US12465653B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022553702A5 (enExample) | ||
| JP2022537158A5 (enExample) | ||
| JP2022549510A5 (enExample) | ||
| JP2023524271A5 (enExample) | ||
| JP2022554094A5 (enExample) | ||
| JP2022546110A5 (enExample) | ||
| JP2024099041A5 (enExample) | ||
| JP2024523453A5 (enExample) | ||
| JP2025041725A5 (enExample) | ||
| IL312845B1 (en) | Extacan derivatives, charge-linkers, and their conjugates | |
| JP2023553421A5 (ja) | 抗ｃｅａ免疫複合体、及びその使用 | |
| JP5503872B2 (ja) | 核酸系代謝拮抗剤の高分子誘導体 | |
| CN112752759A (zh) | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物及其方法与用途 | |
| JP6704900B2 (ja) | ポリオキサゾリン抗体薬物複合体 | |
| RU2748992C2 (ru) | Системы доставки для контролируемого высвобождения лекарственного средства | |
| JP2023539715A5 (enExample) | ||
| JP2024545233A5 (enExample) | ||
| WO2017165851A1 (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| JP2023552792A5 (enExample) | ||
| JP2023545096A5 (enExample) | ||
| JP2024511088A5 (enExample) | ||
| JP2022516427A5 (enExample) | ||
| JP2023553808A5 (enExample) | ||
| JP2024501453A5 (enExample) | ||
| WO2024227439A1 (zh) | 具有靶向作用的偶联物及其制备方法和用途 |